Monoclonal Antibody Therapies for High Risk Neuroblastoma
Wayne L Furman Department of Oncology, St. Jude Children’s Research Hospital, Memphis, TN, USACorrespondence: Wayne L FurmanDepartment of Oncology, St. Jude Children’s Research Hospital, 262 Danny Thomas Place, Memphis, TN, 38105, USATel +1-901-595-2403Fax +1– 901-521-9...
Enregistré dans:
Auteur principal: | Furman WL |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/4d92fc6f80074bf6bbc35d6506e3485d |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Spotlight on dinutuximab in the treatment of high-risk neuroblastoma: development and place in therapy
par: Keyel ME, et autres
Publié: (2018) -
A Novel pH-Sensitive Multifunctional DNA Nanomedicine: An Enhanced and Harmless GD2 Aptamer-Mediated Strategy for Guiding Neuroblastoma Antitumor Therapy
par: Zhang L, et autres
Publié: (2021) -
Nanomicellar Lenalidomide–Fenretinide Combination Suppresses Tumor Growth in an MYCN Amplified Neuroblastoma Tumor
par: Orienti I, et autres
Publié: (2020) -
Variable Expression of the Disialoganglioside GD2 in Breast Cancer Molecular Subtypes
par: Ramona Erber, et autres
Publié: (2021) -
How Can We Engineer CAR T Cells to Overcome Resistance?
par: Glover M, et autres
Publié: (2021)